Abstract
Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.
Original language | English (US) |
---|---|
Pages (from-to) | 161-168 |
Number of pages | 8 |
Journal | Clinical Obstetrics and Gynecology |
Volume | 60 |
Issue number | 1 |
DOIs | |
State | Published - 2017 |
Externally published | Yes |
Keywords
- aspirin
- pravastatin
- preeclampsia
- pregnancy
- statins
ASJC Scopus subject areas
- Obstetrics and Gynecology